FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer. (17th November 2020)

• Record Type: Journal Article
• Authors: Anscher, Mitchell S.; Chang, Elaine; Gao, Xin; Gong, Yutao; Weinstock, Chana; Bloomquist, Erik; Adeniyi, Oluseyi; Charlab, Rosane; Zimmerman, Sarah; Serlemitsos‐Day, Maritsa; Ning, Yang Min; Mayrosh, Ruth; Fuller, Barbara; Trentacosti, Ann Marie; Gallagher, Pamela; Bijwaard, Karen; Philip, Reena; Ghosh, Soma; Fahnbulleh, Frances; Diggs, Felicia; Arora, Shaily; Goldberg, Kirsten B.; Tang, Shenghui; Amiri‐Kordestani, Laleh; Pazdur, Richard; Ibrahim, Amna; Beaver, Julia A.
• Is Part Of: Oncologist. Volume 26:Number 2(2021)
• Page Start: 139
• Page End: 146
• Publication Date: 2020-11-17
• Subjects: Metastatic castrate‐resistant prostate cancer -- Rucaparib -- BRCA mutations -- Poly‐(ADP‐ribose) polymerase inhibitors; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1002/onco.13585
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: : The U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib in May 2020 for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)‐associated metastatic castrate‐resistant prostate cancer (mCRPC) who have been treated with androgen receptor‐directed therapy and a taxane. This approval was based on data from the ongoing multicenter, open‐label single‐arm trial TRITON2. The primary endpoint, confirmed objective response rate, in the 62 patients who met the above criteria, was 44% (95% confidence interval [CI]: 31%–57%). The median duration of response was not estimable (95% CI: 6.4 to not estimable). Fifty‐six percent of patients had a response duration of >6 months and 15% >12 months. The safety profile of rucaparib was generally consistent with that of the class of poly‐(ADP‐ribose) polymerase enzyme inhibitors and other trials of rucaparib in the treatment of ovarian cancer. Deaths due to adverse events (AEs) occurred in 1.7% of patients, and 8% discontinued rucaparib because of an AE. Grade 3–4 AEs occurred in 59% of patients. No patients with prostate cancer developed myelodysplastic syndrome or acute myeloid leukemia. The trial TRITON3 in patients with mCRPC is ongoing and is planned to verify the clinical benefit of rucaparib in mCRPC. This article summarizes the FDA thought process and data supporting this accelerated approval. Implications for Practice: The accelerated approval of rucaparib for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)‐associated metastatic castrate‐resistant prostate cancer who have been treated with androgen receptor‐directed therapy and a taxane represents the first approved therapy for this selected patient population. This approval was based on a single‐arm trial demonstrating a confirmed objective response rate greater than that of available therapy with a favorable duration of response and an acceptable toxicity profile. The ongoing trial TRITON3 is verifying the clinical benefit of this drug. Abstract : This article reviews the data and basis for FDA accelerated approval of rucaparib for the first‐line treatment of patients with deleterious BRCA ‐mutated metastatic castrate‐resistant prostate cancer.